Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Daily low-dose aspirin is established for secondary prevention of cardiovascular events.
• Primary prevention use of aspirin is controversial, especially in lower-risk individuals, due to bleeding risks offsetting modest vascular event reduction.
• Diabetes mellitus significantly elevates risk for atherothrombotic events, suggesting potential benefit from aspirin therapy.

Purpose of the Study:

• To review the literature on aspirin for primary prevention.
• To specifically evaluate aspirin's role in primary prevention for individuals with diabetes mellitus.
• To provide arguments for and against aspirin use and a risk-based algorithm for clinical practice.

Main Methods:

• Literature review of aspirin pharmacology.
• Analysis of studies on aspirin for primary prevention in general population.
• Focused review of aspirin's efficacy and safety in patients with diabetes mellitus.

Main Results:

• Aspirin's benefit in primary prevention is modest and can be outweighed by increased bleeding risk (intracranial, gastrointestinal).
• Individuals with diabetes mellitus have a higher risk of vascular events, making them potential candidates for aspirin therapy.
• The decision to initiate aspirin requires careful risk-benefit assessment.

Conclusions:

• Aspirin's role in primary prevention requires individualized, risk-based decision-making.
• The increased atherothrombotic risk in diabetes mellitus warrants consideration of aspirin therapy.
• A practical algorithm is proposed to guide aspirin initiation in clinical practice.